AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01511991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane dosage titration
Description: comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
Study NCT00004180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Study NCT00931060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids
Description: Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
Study NCT04185051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67953964
Description: Participants will receive JNJ-67953964 as oral capsules.
Study NCT04185051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo oral capsules.
Study NCT02195089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLS_ILS_E710c 500mg
Description: - 2 capsules per day for 20 days (week 1,2,4 \& 8)
Study NCT02761616 — intervention group
Intervention type: OTHER
Intervention: eBC treated participants
Description: No intervention administered in this retrospective observational study.
Study NCT03182816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CTLA-4/PD-1 expressing EGFR-CAR-T
Description: Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
Study NCT00504322 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: AdcuCD40L
Description: Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
Study NCT00504322 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be the salt water-sugar solution used as a vehicle for the vector.
Study NCT02195089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLS_ILB_710c 1000mg
Description: - 4 capsules per day for 20 days (week 1,2,4 \& 8)
Study NCT02195089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLS_ILS_E710c 1500mg
Description: - 6 capsules per day for 8 weeks (week 1,2,4 \& 8)
Study NCT01673438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldoxorubicin
Study NCT00311402 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aggrenox capsule
Description: extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
Study NCT00311402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acetylsalicylic Acid (ASA)
Description: Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
Study NCT03568279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-handed jaw thrust
Description: The assistant applied two-handed jaw thrust for intubation.
Study NCT03568279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The intubation was done without two-handed jaw thrust.
Study NCT01476618 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT03506906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sleep studies under noninvasive ventilation therapy
Description: Polysomnography Transcutaneous capnography
Study NCT00698776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
Study NCT00698776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monocyte derived DCs loaded with KRN7000
Description: 10 million DCs injected intravenously
Study NCT02427867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Study NCT03506906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine tests
Description: Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
Study NCT02200211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad®
Description: Binocular therapy on iPad®
Study NCT02200211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching 2 hours per day, 7 days per week
Study NCT02414997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
Study NCT02414997 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
Study NCT00956020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin matrix
Description: Single treatment with platelet rich fibrin matrix
Study NCT02427867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no ischemic preconditioning
Study NCT01190020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
Study NCT01190020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubiprostone Control
Description: Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
Study NCT02967770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecularly Tailored Second Line Therapy
Description: This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
Study NCT02967770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Second Line Therapy
Study NCT02829775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Participants will maintain the same dose they were receiving in the parent protocol.
Study NCT02829775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa 2a
Description: Participants will maintain the same dose they were receiving in the parent protocol.
Study NCT02788591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Proton Pump Inhibitor (PPI) Therapy
Description: Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
Study NCT02788591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sucralfate
Description: Subject will take Sucralfate 4 times a day for 8 weeks.
Study NCT02212080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1214784
Description: Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
Study NCT02212080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
Study NCT03506906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine tests
Description: Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
Study NCT00015340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Study NCT02890654 — intervention group
Intervention type: OTHER
Intervention: First time measure
Description: * Initial Interview~* Initial Survey,~* Quality of life Scale~* Kinesitherapy Review~* Anxiety Scale
Study NCT02890654 — intervention group
Intervention type: OTHER
Intervention: Second time measure
Description: * Kinesitherapy review~* Second survey including numeric scale of pain~* Anxiety scale~* Scoliosis Research Society 22 quality of life scale
Study NCT02890654 — intervention group
Intervention type: OTHER
Intervention: Third time measure
Description: * Scoliosis Research Society 22 quality of life Scale~* Anxiety scale~* Numeric scale of pain~* Kinesitherapy review
Study NCT00707382 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: (1) Genotyping for CYP4502D6 and 2C19 polymorphisms
Description: In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described.
Study NCT00707382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: (2) Intense clinical monitoring
Description: In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
Study NCT00707382 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: (3) Control
Description: In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
Study NCT02554136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918
Study NCT02550990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Study NCT02550990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Study NCT02550990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential combination of aerobic exercise and cognitive training
Study NCT03478332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yangxinshi pill
Description: 0.6g/tablet
Study NCT03478332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional coronary heart disease medicine
Description: the conventional treatment includes medicines treating coronary heart disease
Study NCT03478332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional coronary heart disease medicine
Description: the conventional treatment includes medicines treating coronary heart disease
Study NCT03478332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Yangxinshi simulant
Study NCT03323541 — intervention group
Intervention type: DRUG
Intervention: Filgrastim Prefilled Syringe [Zarzio®]
Description: Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils >1 giga/l)
Study NCT02143323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin tablet
Study NCT03590093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
Study NCT03590093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
Study NCT03590093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMD application
Description: Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
Study NCT02820038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Guides
Description: The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
Study NCT02820038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Guides
Description: The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
Study NCT01687998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered Orally
Study NCT01687998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study NCT01898806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 2.5 mg/ml
Description: Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
Study NCT01898806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 5 mg/ml
Description: Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
Study NCT01898806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 10 mg/ml
Description: Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
Study NCT01898806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralesional Saline
Description: Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
Study NCT02820038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Program
Description: The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
Study NCT02820038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug Facts Boxes
Description: The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
Study NCT03209011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study NCT03658798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
Study NCT04295707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime
Study NCT04295707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime
Study NCT04295707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menicon Progent A+B
Description: Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
Study NCT01766544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice Group (SPG)
Description: The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
Study NCT01766544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TISG
Description: interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
Study NCT01000818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518 (Raltegravir)
Description: 400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
Study NCT01000818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
Study NCT01000818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: 20 mg oral tablet of omeprazole, once daily for 5 days
Study NCT02979561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.